Ann Dermatol.  2015 Dec;27(6):791-792. 10.5021/ad.2015.27.6.791.

Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib

• Yun HJ
• Seo YJ
• Lee HJ

• KMID: 2157470
• DOI: http://doi.org/10.5021/ad.2015.27.6.791

Abstract

No abstract available.

MeSH Terms

Hair*
Protein-Tyrosine Kinases*
Tyrosine*
Protein-Tyrosine Kinases
Tyrosine

Figure

• 

  Fig. 1 Hair changes before (A) and after (B and C) the treatment with pazopanib.

Reference

1. Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol. 2006; 142:1477–1479.

2. Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther. 2003; 307:476–480.

3. Al-Marrawi MY, Rini B. Pazopanib for the treatment of renal cancer. Expert Opin Pharmacother. 2011; 12:1171–1189.

4. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369:722–731.

5. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28:1061–1068.

6. Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 2008; 144:1525–1526.